Management of GERD in Patients with Heart Failure

First-Line Pharmacological Management

The American Gastroenterological Association recommends proton pump inhibitors (PPIs) as first-line therapy for GERD in heart failure patients due to their superior efficacy in healing esophagitis and providing symptomatic relief compared to histamine-2 receptor antagonists (H2RAs) 1, 3
The American College of Cardiology suggests starting with standard once-daily PPI dosing (e.g., omeprazole 20mg daily) for uncomplicated GERD symptoms 2, 4
If symptoms persist after 4-8 weeks of once-daily PPI therapy, dosing can be increased to twice daily, with consideration of potential drug interactions with heart failure medications 1, 4, 5

The European Society of Cardiology recommends avoiding metoclopramide as monotherapy or adjunctive therapy for GERD in heart failure patients due to lack of efficacy and potential adverse effects 1, 3
The American Heart Association advises against using calcium channel blockers like diltiazem or verapamil in patients with heart failure with reduced ejection fraction (HFrEF) as they can worsen heart failure symptoms 5

The American Gastroenterological Association suggests empiric PPI therapy is appropriate without initial endoscopy for patients with typical GERD symptoms (heartburn, regurgitation) without alarm features 2, 4
Endoscopy should be considered for patients who have not responded to twice-daily PPI therapy after 8 weeks, or those with alarm symptoms (dysphagia, bleeding, anemia, weight loss, recurrent vomiting) 1, 2, 3

The American Gastroenterological Association recommends targeted lifestyle modifications, including elevation of the head of the bed for patients with nighttime symptoms, avoidance of specific trigger foods, weight loss for overweight or obese patients, and avoiding recumbency for 2-3 hours after meals 3, 7

The European Society of Cardiology advises monitoring for potential interactions between PPIs and heart failure medications, particularly with clopidogrel if the patient has coronary artery disease 5
For patients with heart failure and refractory GERD symptoms, ambulatory pH or impedance-pH monitoring should be considered to confirm diagnosis before escalating therapy 1
The American College of Cardiology recommends using the lowest effective dose of PPIs to minimize potential adverse effects in patients with heart failure requiring long-term PPI therapy 2, 4

The American Gastroenterological Association suggests potassium-competitive acid blockers (P-CABs) like vonoprazan may be considered in patients with severe GERD who have failed PPI therapy, though more data is needed in heart failure patients specifically 8
For obese patients with both GERD and heart failure, Roux-en-Y gastric bypass may be considered as it can improve both conditions, while sleeve gastrectomy may worsen GERD 4